Showing 1721-1730 of 9129 results for "".
DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneFinally: JAK Inhibitors Are Here
https://practicaldermatology.com/topics/psoriasis/finally-jak-inhibitors-are-here/20076/JAK inhibitors reach across all of dermatology, says Brett King, MD, PhD, who says the existing data is impressive and even more data are forthcoming for this class of medicine that will "change the landscape of dermatology."Contact Derm and AD Updates
https://practicaldermatology.com/conferences/maui-derm-2022/contact-derm-and-ad-updates/20052/Matthew Zirwas, MD reviews allergens that have made the list of Allergen of the Year over the program's 20-year history and what dermatologists should know about these allergens. He also provides an overview of his approach to diagnosing and treating atopic dermatitis.DermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PSkin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new cancDermWireTV: Derm Salaries Down, Allergan Eyes Soliton, Emsculpt Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-derm-salaries-down-allergan-eyes-soliton-emsculpt-week/19941/Just under half of all physicians in the US are employed in physician-owned medical practices, new data from the American Medical Association show. Medscape’s annual Physician Compensation Report reveals that physicians overall saw a reduction in income due to the COVID-19 pandemic; income for dermThe Expanding Role for PD-1 Inhibitors for NMSCs
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-expanding-role-for-pd-1-inhibitors-for-nmscs/19937/The pool of potential patients that could be treated with PD-1 inhibitors is growing. Todd Schlesinger, MD discusses how these drugs may be used to treat a greater number of patients with NMSCs and addresses side effects and their management.The Time is Now: Dermatology and Climate Change
https://practicaldermatology.com/topics/practice-management/the-time-is-now-dermatology-and-climate-change/19930/How are global warming and associated changes in weather affecting the presentation of skin diseases? And what opportunities do dermatologists have to help turn the tide of global warning? Misha Rosenbach, MD reviews the science and touches on opportunities for change.Opportunities and Barriers in Teledermatology
https://practicaldermatology.com/conferences/aad-2021/opportunities-and-barriers-in-teledermatology/19923/Dermatologists' participation in telemedicine has increased exponentially over the past year. But what does the future hold? What opportunities exist and what challenges remain? Jules Lipoff, MD weighs in.